Back A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® Signs Strategic Partnership Agreement with China Medical Instrument


Shanghai, China – Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") recently signed a strategic partnership agreement with China Medical Instrument (Group) Co., Ltd. ("China Medical Instrument").
The signing ceremony took place in MicroPort® Shanghai headquarters and the senior management team of China Medical Instrument, China Pharmaceutical Group Shanghai Medical Instrument Co., Ltd., and MicroPort®'s business segments including cardiovascular, orthopedic, EP, neurovascular, cardiac rhythm management, surgical, endovascular, and lifesciences attended the ceremony.
China Medical Instrument is a subsidiary of the largest healthcare company in China - China National Pharmaceutical Group Corporation ("SINOPHARM"), covering various business segments including sales, logistics, group purchasing, government centralizing procurement, and international trade. It is a strong player in distributing, retailing, developing and manufacturing medical devices.
MicroPort® Chief Marketing Officer Bo Peng said, "This partnership brings together two industry leaders. It is expected that this partnership will allow MicroPort® to leverage SINOPHARM's broad distribution channels and policy advantages and lay a good foundation for further cooperation. By sharing resources and leveraging complementary advantages in logistics and service, we hope to jointly promote the development of medical devices."

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to:

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2018 MicroPort Scientific Corporation

Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6953


[Prev]:MicroPort® Attends CIT 2017 and Releases One-year Clinical and Angiographic Results of Firesorb® FUTURE I Trial
[Next]:MicroPort® Endovascular Attends 2017 Vascular Innovative Forum